Venture capital investment in gene therapy is declining, with a 61% drop in deals from 2021 to 2025. Companies are now focusing on more derisked targets like obesity drugs and antibody-drug conjugates. The average value of gene therapy deals is $60m in 2025, far lower than other modalities. Big pharma is looking to acquire CGT technologies rather than develop in-house. Eli Lilly has been active in gene therapy deals, spending millions on ophthalmology gene therapy acquisitions. As the CGT market is expected to grow by 34.2% by 2031, companies must prepare for challenges in regulation and manufacturing scalability.

Read more at Yahoo Finance: Cell and gene therapy investment strategy pivots as funding dries up